Un-audited Results of the Company for the quarter ended 30th June 2025 along with Limited review report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals posted strong Q1 FY26 results, with standalone net sales rising to Rs 11,940.29 lakhs from Rs 7,753.58 lakhs in Q1 FY25 — a jump of about 54%. Total operating income rose to Rs 11,985.50 lakhs from Rs 7,881.08 lakhs. Profit before tax climbed to Rs 904.04 lakhs (vs Rs 551.90 lakhs), and profit after tax grew to Rs 676.58 lakhs (vs Rs 412.99 lakhs), a roughly 64% increase year-on-year. Basic EPS stood at Rs 14.33, up from Rs 8.79. The consolidated numbers mirror the standalone figures, indicating subsidiaries are still in early-stage or non-operational status. Statutory auditor R.H. Nisar & Co. issued a clean (unmodified) limited review opinion on both standalone and consolidated results. The board also appointed Mr. Anshu Agarwal and Ms. Sonal Desai as Independent Directors for a five-year term.
Strong top-line and bottom-line growth signals healthy business momentum and is likely to be viewed positively by shareholders. The clean audit opinion and fresh independent director appointments add to governance comfort, potentially supporting investor sentiment.